HhAntag
CAS No. 496794-70-8
HhAntag( HhAntag | Hh-Antag | Hh Antag )
Catalog No. M17525 CAS No. 496794-70-8
HhAntag is a small molecule inhibitor of GLI1-mediated transcription, an essential down-stream element of the Hedgehog (Hh) pathway with the anti-tumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 101 | In Stock |
|
| 5MG | 93 | In Stock |
|
| 10MG | 170 | In Stock |
|
| 25MG | 359 | In Stock |
|
| 50MG | 602 | In Stock |
|
| 100MG | 918 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHhAntag
-
NoteResearch use only, not for human use.
-
Brief DescriptionHhAntag is a small molecule inhibitor of GLI1-mediated transcription, an essential down-stream element of the Hedgehog (Hh) pathway with the anti-tumor activity.
-
DescriptionHhAntag is a GLI1-mediated transcription inhibitor. It acts as an inhibitor of the Shh pathway.
-
In VitroHhAntag (2-30 μM; 72?hours) demonstrates to be?10-times more potent than the natural product SMO antagonist, cyclopamine, at inhibiting Hh pathway activity and it inhibits Hh signalling pathway sensitivitive cells with IC50 values ranging from 2?μM to >30?μM.HhAntag inhibits AsPC-1, BXPC-3, CFPAC, HPAC, HPAF-II, KP4, Panc 03.27, PA-TU-8902, PSN-1, SU.86.86 cells with IC50 values of 30 μM, 5.4 μM, 5.8 μM, 2.7 μM, 6.2 μM,10.3 μM, 2.5 μM, 2.9 μM, 5.8 μM and 2.7 μM, respectively.HhAntag (100 nM) is needed to completely inhibit Hh signalling in a Hh-responsive human mesenchymal cell line (HEPM) expressing a?GLI?luciferase reporter construct (HEPM-rep), the IC50?of 5?nM 400-times lower than that required to inhibit cell growth by 50% in the most sensitive cancer cell line (1.9?μM).
-
In VivoHhAntag (oral administraion; 75 mg/kg or 100 mg/kg; twice daily; 25 days) results in significant growth delay in HT55 and HT-29 colorectal cell line xenografts models, with average tumour growth inhibitions of 29% and 48%, respectively. Whereas HhAntag had no effect on the growth of DLD-1 xenografts. Animal Model:Primary human xenografts?in?female CD1 nu/nu mice of 6–8?weeks (DLD-1, HT55 and HT-29 cells)Dosage:75 mg/kg or 100 mg/kg Administration:Oral administraion; twice daily; 25 days Result:Resulted in growth delay of HT55 and HT-29 xenografts, but had no effects on DLD-1 xenografts.
-
SynonymsHhAntag | Hh-Antag | Hh Antag
-
PathwayMembrane Transporter/Ion Channel
-
TargetTRP/TRPV Channel
-
RecptorGli
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number496794-70-8
-
Formula Weight450.92
-
Molecular FormulaC24H23ClN4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL. 221.77 mM; H2O : < 0.1 mg/mL
-
SMILESC(=O)(c1cc(cc(c1)OC)OC)Nc1cc(c(cc1)Cl)c1nc2c([nH]1)cc(cc2)N(C)C
-
Chemical NameN-[4-Chloro-3-[6-(dimethylamino)-1H-benzimidazol-2-yl]phenyl]-3,5-dimethoxybenzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Actis, Marcelo; Connelly, Michele C.; Mayasundari, Anand et al. Biopolymers (2011), 95(1), 24-30.
molnova catalog
related products
-
TRPM4-IN-2
TRPM4-IN-2 (NBA), also known as NBA, is a highly effective inhibitor of transient receptor potential melastatin 4 (TRPM4).
-
TRPC6-PAM-C20
TRPC6-PAM-C20 is a selective TRPC6 positive allosteric modulator. TRPC6-PAM-C20 induces transient increase in intracellular Ca2+ in HEK cells expressing TRPC6 with an EC50 of 2.37 μM. TRPC6-PAM-C20 enhances OAG-induced platelet aggregation.
-
GSK1702934A
GSK1702934A, a selective TRPC3 agonist, modulates cardiac contractility and arrhythmogenesis through TRPC3 activation.
Cart
sales@molnova.com